zykadia, buy zykadia online , zykadia for sale
Zykadia is a cancer medicine used on its own to treat adults with a type of lung cancer called non-small-cell lung cancer (NSCLC), when the disease is advanced. It is only used if the NSCLC is ‘ALK-positive’, which means that the cancer cells have certain defects affecting the gene responsible for a protein called ALK (anaplastic lymphoma kinase)
how is zykadia used
Zykadia can only be obtained with a prescription and treatment must be started and supervised by a doctor who is experienced in using cancer medicines. The presence of genetic defects affecting ALK (‘ALK-positive’ status) has to be confirmed in advance by appropriate methods.
moreover The medicine is available as capsules (150 mg). The recommended dose is 450 mg (3 capsules) once a day taken with food at the same time each day. The doctor may decide to reduce the dose or stop treatment temporarily if side effects occur. In certain cases treatment should be permanently stopped.
For more information about using Zykadia, see the package leaflet or contact a doctor or pharmacist.
side effects of zykadia
furthermore The most common side effects with Zykadia (which may affect 1 or more people in 10) are diarrhoea, nausea (feeling sick), vomiting, tiredness, abnormal liver tests, abdominal (belly) pain, decreased appetite, weight loss, constipation, rash, increases in the level of a waste product called creatinine in the blood (a possible sign of kidney problems), oesophageal disorder (problems affecting the food pipe) and anaemia (low levels of red blood cells). The most common severe reactions (which may affect 1 or more people
in 20) are abnormal liver tests, tiredness, diarrhoea, nausea, vomiting and hyperglycaemia (high blood sugar). because
and because For the full list of side effects and restrictions with Zykadia, see the package leaflet.
benefits of zykadia
Zykadia has been shown to be effective at treating advanced, ALK-positive NSCLC in three main studies in patients whose disease progressed despite previous treatment with the medicine crizotinib:
because In two of these studies, involving 303 patients, the medicine was not compared with any other treatment. Response to treatment was assessed using body scans and standardised
criteria used for solid tumours, with complete response being when the patient had no remaining signs of the cancer. In one study 56% of patients given (92 of 163) were considered
by the treating doctors to have shown a complete or partial response to the medicine. The average length of response was 8.3 months. In the second study, the overall response rate was 41% (57 of 140 patients) and the average length of response was 10.6 months.
In the third study in 231 patients, was compared with standard chemotherapy (medicines to treat cancer). Results showed that patients given Zykadia lived for an average of 5.4 months without their disease getting worse (progression-free survival) compared with 1.6 months in patients given standard chemotherapy.
Zykadia has also been shown to be effective at treating
patients who had not been treated before in a study in 376 patients. Patients given Zykadia lived for an average of 16.6
months without their disease getting worse compared with 8.1 months in patients given standard chemotherapy.